Publications

Publications

Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment

By:
Contributors: Robert Paproski, PhD, Ronald Moore Research Group
J Biomed Opt. 2014 May;19(5):056014. doi: 10.1117/1.JBO.19.5.056014.

Abstract

While more than 90% of cancer deaths are due to metastases, our ability to detect circulating tumor cells (CTCs) is limited by low numbers of these cells in the blood and factors confounding specificity of detection. We propose a magnetic enrichment and detection technique for detecting CTCs with high specificity. We targeted both magnetic and surface-enhanced Raman scattering (SERS) nanoparticles to cancer cells. Only cells that are dual-labeled with both kinds of nanoparticles demonstrate an increasing SERS signal over time due to magnetic trapping.

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Nanostics is pleased to announce the launch of clinical validation study

EDMONTON, June 4, 2019 /CNW/ – Nanostics Inc. is pleased to Announce the start of its key Clinical validation study. APCaRI is managing the study and recruitment has begun at Calgary’s Prostate Cancer Centre (PCC) and Edmonton’s Northern Alberta Urology Centre (NAUC). Recruitment of men from the Yukon Territories will follow.
The study will be conducted in partnership with DynaLIFE Medical Labs with co-principal investigators Dr. Eric Hyndman (PCC) and Dr. Adrian Fairey’s (NAUC).
Nanostics recognizes and is very grateful for the funding and support we received from the Bird Dogs from the beginning of this research and development journey. Nanostics also thanks funders for the clinical study including the Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.

- Unknown